Clinical-stage CAR-T company is actively recruiting patients to evaluate SynKIR™-110, a new treatment candidate for ovarian cancer, mesothelioma, and cholangiocarcinoma…
Conference call and webcast: today, March 7, 2024, 9:00 am E.T. +1-888-407-2553 or +972-3- 9180608 I https://veidan.activetrail.biz/evogeneq4-2023 REHOVOT, Israel, March…
Initial interim data show favorable drug exposure and confirm ALG.APV-527 biological activityEarly promising signs of clinical activity in heavily pretreated…
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer),…
Moffitt’s preclinical findings strongly suggest PV-10 induces immunogenic cell death-associated immunogenicity in HPV-positive and HPV-negative HNSCC in vitro and in…
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses…
– Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first…
Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean…
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on…
BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and…